accessibility menu, dialog, popup

UserName
Viewing profile as user:

Pyrroles

Aromatic organic heterocyclic compounds that consist of a five-membered ring with four carbon atoms and one nitrogen atom that forms an amine functional group.

Filtered Search Results

Products from some of our suppliers do not display in filtered search results. Please clear all filters to see these products.

Narrow Results

Narrow Results

category

brands

  • (3)

special interests

  • (3)

Search Within Results
Keyword Search:
1 – 3 of 3 results
1

Apexbio Technology LLC Sunitinib 557795-19-4 100mg
SDP

Sunitinib (CAS 557795-19-4) is an orally bioavailable small molecule inhibitor targeting multiple receptor tyrosine kinases (RTKs) including VEGFR1-3 PDGFR / c-kit and RET Research has shown sunitinib inhibits proliferation in nasopharyngeal carcinoma (NPC) cell lines HK1 CNE-1 CNE-2 HONE-1 and C666-1 with IC50 values ranging from approximately 2 06 to 7 57 M Additionally it induces apoptosis and G0/G1 cell cycle arrest in NPC cell lines and significantly decreases microvessel density in CNE-2 xenograft tumor models in vivo Thus sunitinib is useful for investigating pathways involved in tumor angiogenesis and proliferation

ENCOMPASS_PREFERRED
2

Apexbio Technology LLC Sunitinib 557795-19-4 10mM (in 1mL DMSO)
SDP

Sunitinib (CAS 557795-19-4) is an orally bioavailable small molecule inhibitor targeting multiple receptor tyrosine kinases (RTKs) including VEGFR1-3 PDGFR / c-kit and RET Research has shown sunitinib inhibits proliferation in nasopharyngeal carcinoma (NPC) cell lines HK1 CNE-1 CNE-2 HONE-1 and C666-1 with IC50 values ranging from approximately 2 06 to 7 57 M Additionally it induces apoptosis and G0/G1 cell cycle arrest in NPC cell lines and significantly decreases microvessel density in CNE-2 xenograft tumor models in vivo Thus sunitinib is useful for investigating pathways involved in tumor angiogenesis and proliferation

ENCOMPASS_PREFERRED
3

Apexbio Technology LLC Sunitinib 557795-19-4 1g
SDP

Sunitinib (CAS 557795-19-4) is an orally bioavailable small molecule inhibitor targeting multiple receptor tyrosine kinases (RTKs) including VEGFR1-3 PDGFR / c-kit and RET Research has shown sunitinib inhibits proliferation in nasopharyngeal carcinoma (NPC) cell lines HK1 CNE-1 CNE-2 HONE-1 and C666-1 with IC50 values ranging from approximately 2 06 to 7 57 M Additionally it induces apoptosis and G0/G1 cell cycle arrest in NPC cell lines and significantly decreases microvessel density in CNE-2 xenograft tumor models in vivo Thus sunitinib is useful for investigating pathways involved in tumor angiogenesis and proliferation

ENCOMPASS_PREFERRED